Table of Contents Author Guidelines Submit a Manuscript
Advances in Urology
Volume 2012, Article ID 135281, 5 pages
http://dx.doi.org/10.1155/2012/135281
Review Article

Circulating and Disseminated Tumor Cells in the Management of Advanced Prostate Cancer

Department of Urology, Eberhard-Karls University, Hoppe Seyler-Straße 3, 72076 TÜbingen, Germany

Received 2 June 2011; Accepted 5 June 2011

Academic Editor: Maximilian Burger

Copyright © 2012 Stephan Kruck et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Heidenreich, G. Aus, M. Bolla et al., “EAU guidelines on prostate cancer,” Actas Urologicas Espanolas, vol. 33, no. 2, pp. 113–126, 2009. View at Google Scholar · View at Scopus
  2. E. Okajima and T. Kotake, “Management of advanced urogenital cancer: treatment of metastasis,” Hinyokika Kiyo, vol. 40, no. 10, pp. 905–907, 1994. View at Google Scholar · View at Scopus
  3. T. G. Lugo, S. Braun, R. J. Cote, K. Pantel, and V. Rusch, “Detection and measurement of occult disease for the prognosis of solid tumors,” Journal of Clinical Oncology, vol. 21, no. 13, pp. 2609–2615, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. I. Funke and W. Schraut, “Meta-analyses of studies on bone marrow micrometastases: an independent prognostic impact remains to be substantiated,” Journal of Clinical Oncology, vol. 16, no. 2, pp. 557–566, 1998. View at Google Scholar · View at Scopus
  5. K. Pantel and R. H. Brakenhoff, “Dissecting the metastatic cascade,” Nature Reviews Cancer, vol. 4, no. 6, pp. 448–456, 2004. View at Google Scholar · View at Scopus
  6. Y. Hüsemann, J. B. Geigl, F. Schubert et al., “Systemic spread is an early step in breast cancer,” Cancer Cell, vol. 13, no. 1, pp. 58–68, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. P. Paterlini-Brechot and N. L. Benali, “Circulating tumor cells (CTC) detection: clinical impact and future directions,” Cancer Letters, vol. 253, no. 2, pp. 180–204, 2007. View at Publisher · View at Google Scholar · View at Scopus
  8. K. Pantel, R. H. Brakenhoff, and B. Brandt, “Detection, clinical relevance and specific biological properties of disseminating tumour cells,” Nature Reviews Cancer, vol. 8, no. 5, pp. 329–340, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. T. R. Asworth, “A case of cancer in which cells similar to those in tumors were seen in the blood after death,” Australasian Medical Journal, vol. 14, pp. 146–114, 1869. View at Google Scholar
  10. U. Bilkenroth, H. Taubert, D. Riemann, U. Rebmann, H. Heynemann, and A. Meye, “Detection and enrichment of disseminated renal carcinoma cells from peripheral blood by immunomagnetic cell separation,” International Journal of Cancer, vol. 92, no. 4, pp. 577–582, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. T. A. Masuda, A. Kataoka, S. Ohno et al., “Detection of occult cancer cells in peripheral blood and bone marrow by quantitative RT-PCR assay for cytokeratin-7 in breast cancer patients,” International Journal of Oncology, vol. 26, no. 3, pp. 721–730, 2005. View at Google Scholar · View at Scopus
  12. G. Wiedswang, E. Borgen, C. Schirmer et al., “Comparison of the clinical signiicance of occult tumor cells in blood and bone marrow in breast cancer,” International Journal of Cancer, vol. 118, no. 8, pp. 2013–2019, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. R. Rosenberg, R. Gertler, J. Friederichs et al., “Comparison of two density gradient centrifugation systems for the enrichment of disseminated tumor cells in blood,” Cytometry, vol. 49, no. 4, pp. 150–158, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Trzpis, P. M. J. McLaughlin, L. M. F. H. De Leij, and M. C. Harmsen, “Epithelial cell adhesion molecule: more than a carcinoma marker and adhesion molecule,” American Journal of Pathology, vol. 171, no. 2, pp. 386–395, 2007. View at Publisher · View at Google Scholar · View at Scopus
  15. C. H. Wu, S. R. Lin, J. S. Hsieh et al., “Molecular detection of disseminated tumor cells in the peripheral blood of patients with gastric cancer: evaluation of their prognostic significance,” Disease Markers, vol. 22, no. 3, pp. 103–109, 2006. View at Google Scholar · View at Scopus
  16. N. Gerges, J. Rak, and N. Jabado, “New technologies for the detection of circulating tumour cells,” British Medical Bulletin, vol. 94, no. 1, pp. 49–64, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. J. S. de Bono, H. I. Scher, R. B. Montgomery et al., “Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer,” Clinical Cancer Research, vol. 14, no. 19, pp. 6302–6309, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. M. Cristofanilli, K. R. Broglio, V. Guarneri et al., “Circulating tumor cells in metastatic breast cancer: biologic staging beyond tumor burden,” Clinical Breast Cancer, vol. 7, no. 6, pp. 471–479, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Naoe, Y. Ogawa, K. Takeshita, S. Iwamoto, and A. Miyazaki, “Use of the CellSearch circulating tumor cell test for monitoring urothelial cancer: two case reports of metastatic urothelial cancer,” Southern Medical Journal, vol. 101, no. 4, pp. 439–441, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. J. Wind, J. B. Tuynman, A. G. J. Tibbe et al., “Circulating tumour cells during laparoscopic and open surgery for primary colonic cancer in portal and peripheral blood,” European Journal of Surgical Oncology, vol. 35, no. 9, pp. 942–950, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. R. A. Ghossein, H. I. Scher, W. L. Gerald et al., “Detection of circulating tumor cells in patients with localized and metastatic prostatic carcinoma: clinical implications,” Journal of Clinical Oncology, vol. 13, no. 5, pp. 1195–1200, 1995. View at Google Scholar · View at Scopus
  22. M. V. Seiden, P. W. Kantoff, K. Krithivas et al., “Detection of circulating tumor cells in men with localized prostate cancer,” Journal of Clinical Oncology, vol. 12, no. 12, pp. 2634–2639, 1994. View at Google Scholar · View at Scopus
  23. P. Bossolasco, C. Ricci, G. Farina et al., “Detection of micrometastatic cells in breast cancer by RT-PCR for the mammaglobin gene,” Cancer Detection and Prevention, vol. 26, no. 1, pp. 60–63, 2002. View at Publisher · View at Google Scholar · View at Scopus
  24. P. Helo, A. M. Cronin, D. C. Danila et al., “Circulating prostate tumor cells detected by reverse transcription-PCR in men with localized or castration-refractory prostate cancer: concordance with CellSearch assay and association with bone metastases and with survival,” Clinical Chemistry, vol. 55, no. 4, pp. 765–773, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Nagrath, L. V. Sequist, S. Maheswaran et al., “Isolation of rare circulating tumour cells in cancer patients by microchip technology,” Nature, vol. 450, no. 7173, pp. 1235–1239, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. A. Meye, U. Bilkenroth, U. Schmidt et al., “Isolation and enrichment of urologic tumor cells in blood samples by a semi-automated CD45 depletion autoMACS protocol,” International journal of oncology, vol. 21, no. 3, pp. 521–530, 2002. View at Google Scholar · View at Scopus
  27. K. Bluemke, U. Bilkenroth, A. Meye et al., “Detection of circulating tumor cells in peripheral blood of patients with renal cell carcinoma correlates with prognosis,” Cancer Epidemiology Biomarkers and Prevention, vol. 18, no. 8, pp. 2190–2194, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. K. Blümke, U. Bilkenroth, U. Schmidt et al., “Detection of circulating tumor cells from renal carcinoma patients: experiences of a two-center study,” Oncology Reports, vol. 14, no. 4, pp. 895–899, 2005. View at Google Scholar · View at Scopus
  29. T. Hioki and Y. Sugimura, “Detection of circulating cancer cells by nested reverse transcription-polymerase chain reaction of cytokeratin-19 in patients with renal cell carcinoma,” Hinyokika Kiyo, vol. 45, no. 8, pp. 577–581, 1999. View at Google Scholar · View at Scopus
  30. J. M. McKiernan, R. Buttyan, N. H. Bander et al., “The detection of renal carcinoma cells in the peripheral blood with an enhanced reverse transcriptase-polymerase chain reaction assay for MN/CA9,” Cancer, vol. 86, no. 3, pp. 492–497, 1999. View at Publisher · View at Google Scholar · View at Scopus
  31. T. Shimazui, K. Yoshikawa, H. Uemura et al., “Detection of cadherin-6 mRNA by nested RT-PCR as a potential marker for circulating cancer cells in renal cell carcinoma,” International Journal of Oncology, vol. 23, no. 4, pp. 1049–1054, 2003. View at Google Scholar · View at Scopus
  32. S. Ashida, H. Okuda, M. Chikazawa et al., “Detection of circulating cancer cells with von Hippel-Lindau gene mutation in peripheral blood of patients with renal cell carcinoma,” Clinical Cancer Research, vol. 6, no. 10, pp. 3817–3822, 2000. View at Google Scholar · View at Scopus
  33. G. Li, K. Passebosc-Faure, A. Gentil-Perret, C. Lambert, C. Genin, and J. Tostain, “Cadherin-6 gene expression in conventional renal cell carcinoma: a useful marker to detect circulating tumor cells,” Anticancer Research, vol. 25, no. 1A, pp. 377–381, 2005. View at Google Scholar · View at Scopus
  34. A. Buchner, R. Riesenberg, I. Kotter, A. Crispin, A. Hofstetter, and R. Oberneder, “Detection and prognostic value of cytokeratin positive tumor cells in bone marrow of patients with renal cell carcinoma,” Journal of Urology, vol. 170, no. 5, pp. 1747–1751, 2003. View at Publisher · View at Google Scholar · View at Scopus
  35. A. Buchner, R. Riesenberg, I. Kotter, A. Hofstetter, C. Stief, and R. Oberneder, “Frequency and prognostic relevance of disseminated tumor cells in bone marrow of patients with metastatic renal cell carcinoma,” Cancer, vol. 106, no. 7, pp. 1514–1520, 2006. View at Publisher · View at Google Scholar · View at Scopus
  36. M. Naoe, Y. Ogawa, J. Morita et al., “Detection of circulating urothelial cancer cells in the blood using the CellSearch system,” Cancer, vol. 109, no. 7, pp. 1439–1445, 2007. View at Publisher · View at Google Scholar · View at Scopus
  37. M. Rink, F. K. H. Chun, S. Minner et al., “Detection of circulating tumour cells in peripheral blood of patients with advanced non-metastatic bladder cancer,” BJU International, vol. 107, no. 10, pp. 1668–1675, 2011. View at Publisher · View at Google Scholar
  38. A. Gradilone, A. Petracca, C. Nicolazzo et al., “Prognostic significance of survivin-expressing circulating tumour cells in T1G3 bladder cancer,” BJU International, vol. 106, no. 5, pp. 710–715, 2010. View at Publisher · View at Google Scholar · View at Scopus
  39. W. J. Allard, J. Matera, M. C. Miller et al., “Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases,” Clinical Cancer Research, vol. 10, no. 20, pp. 6897–6904, 2004. View at Publisher · View at Google Scholar · View at Scopus
  40. J. G. Moreno, M. C. Miller, S. Gross, W. J. Allard, L. G. Gomella, and L. W. M. M. Terstappen, “Circulating tumor cells predict survival in patients with metastatic prostate cancer,” Urology, vol. 65, no. 4, pp. 713–718, 2005. View at Publisher · View at Google Scholar · View at Scopus
  41. D. C. Danila, G. Heller, G. A. Gignac et al., “Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer,” Clinical Cancer Research, vol. 13, no. 23, pp. 7053–7058, 2007. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Halabi, N. J. Vogelzang, A. B. Kornblith et al., “Pain predicts overall survival in men with metastatic castration-refractory prostate cancer,” Journal of Clinical Oncology, vol. 26, no. 15, pp. 2544–2549, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. V. Ramiah, D. J. George, and A. J. Armstrong, “Clinical endpoints for drug development in prostate cancer,” Current Opinion in Urology, vol. 18, no. 3, pp. 303–308, 2008. View at Publisher · View at Google Scholar · View at Scopus
  44. H. I. Scher, X. Jia, J. S. de Bono et al., “Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data,” The Lancet Oncology, vol. 10, no. 3, pp. 233–239, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. D. R. Shaffer, M. A. Leversha, D. C. Danila et al., “Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer,” Clinical Cancer Research, vol. 13, no. 7, pp. 2023–2029, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. B. T. Chen, R. D. Loberg, C. K. Neeley et al., “Preliminary study of immunomagnetic quantification of circulating tumor cells in patients with advanced disease,” Urology, vol. 65, no. 3, pp. 616–621, 2005. View at Publisher · View at Google Scholar · View at Scopus
  47. H. Schwarzenbach, C. Alix-Panabières, I. Müller et al., “Cell-free tumor DNA in blood plasma as a marker for circulating tumor cells in prostate cancer,” Clinical Cancer Research, vol. 15, no. 3, pp. 1032–1038, 2009. View at Publisher · View at Google Scholar · View at Scopus